Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilorasertib + carboplatin
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ilorasertib (ABT-348) is an orally active, ATP-competitive small molecule multikinase inhibitor that primarily targets Aurora kinases (A, B, and C), as well as members of the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families. Carboplatin is a platinum-based chemotherapeutic agent that functions by interfering with DNA replication through the formation of DNA cross-links. This combination therapy was developed by AbbVie (formerly Abbott) and evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors. The study aimed to determine the safety, pharmacokinetics, and maximum tolerated dose of the combination. However, the development program for ilorasertib, including its use in combination with carboplatin, was ultimately discontinued.
- Brand names
- ParaplatinCARBOplatin Novaplus
- Other names
- ilorasertib + carboplatin
02
Targets
AURKB (Aurora kinase B)PDGFRB (Platelet-derived growth factor receptor beta)SFK (SRC family kinases)PDGFRA (Platelet-derived growth factor receptor alpha)CSF1R (Macrophage colony-stimulating factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)AURKA (Aurora kinase A)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)AURKC (Aurora kinase C)
Beyond the preview
Go deeper on ilorasertib + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilorasertib + carboplatin.